A Phase IV, International, Open-Label, Randomised, Cross-Over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.

Trial Profile

A Phase IV, International, Open-Label, Randomised, Cross-Over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms SAPHE
  • Sponsors Ipsen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 Results of pooled analysis (n=378) of 5 clinical trials (NCT00353496, NCT00842348, NCT00774930, NCT00681187 and NCT00326469) presented at the 2017 Gastrointestinal Cancers Symposium
    • 17 Mar 2012 Planned number of patients changed from 26 to 42 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top